These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30712411)

  • 1. The link between anemia and adverse outcomes in patients with acute coronary syndrome.
    Guedeney P; Sorrentino S; Claessen B; Mehran R
    Expert Rev Cardiovasc Ther; 2019 Mar; 17(3):151-159. PubMed ID: 30712411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
    Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline anemia in patients undergoing percutaneous coronary intervention after an acute coronary syndrome-A paradox of high bleeding risk, high ischemic risk, and complex coronary disease.
    Yazji K; Abdul F; Elangovan S; Ul Haq MZ; Ossei-Gerning N; Morris K; Anderson R; Kinnaird T
    J Interv Cardiol; 2017 Oct; 30(5):491-499. PubMed ID: 28707308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prasugrel hydrochloride for the treatment of acute coronary syndrome patients.
    Gunarathne A; Hussain S; Gershlick AH
    Expert Rev Cardiovasc Ther; 2016 Nov; 14(11):1215-1226. PubMed ID: 27701930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial.
    Costa F; Vranckx P; Leonardi S; Moscarella E; Ando G; Calabro P; Oreto G; Zijlstra F; Valgimigli M
    Eur Heart J; 2015 May; 36(20):1242-51. PubMed ID: 25718355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.
    Ganetsky VS; Hadley DE; Thomas TF
    Pharmacotherapy; 2014 Jun; 34(6):590-604. PubMed ID: 24338703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anemia, hemorrhage, and transfusion in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction.
    Willis P; Voeltz MD
    Am J Cardiol; 2009 Sep; 104(5 Suppl):34C-8C. PubMed ID: 19695359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy.
    Hamilos M; Petousis S; Xanthopoulou I; Goudevenos J; Kanakakis J; Sitafidis G; Vavouranakis M; Skalidis E; Kochiadakis G; Lekakis J; Vardas PE; Alexopoulos D
    Coron Artery Dis; 2018 Jan; 29(1):53-59. PubMed ID: 28834792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors and Management of Antiplatelet-Related Bleeding Complications for Acute Coronary Syndrome in Chinese Elderly Patients.
    Wan J; Wang P; Zhou P; Liu S; Wang D; Kan J; Hou J; Zuo L; Ma S; Yang Y
    Cell Physiol Biochem; 2018; 50(3):1164-1177. PubMed ID: 30355936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial.
    Lee JM; Cho DK; Hahn JY; Song YB; Park TK; Oh JH; Lee JB; Doh JH; Kim SH; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC
    Am Heart J; 2016 Dec; 182():1-8. PubMed ID: 27914488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice.
    Muñiz-Lozano A; Rollini F; Franchi F; Angiolillo DJ
    Ther Adv Cardiovasc Dis; 2013 Aug; 7(4):197-213. PubMed ID: 23818658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    Camaro C; Damen SA; Brouwer MA; Kedhi E; Lee SW; Verdoia M; Barbieri L; Rognoni A; van T Hof AW; Ligtenberg E; de Boer MJ; Suryapranata H; De Luca G
    Am Heart J; 2016 Aug; 178():37-44. PubMed ID: 27502850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial).
    Goto K; Lansky AJ; Ng VG; Pietras C; Nargileci E; Mehran R; Parise H; Feit F; Ohman EM; White HD; Bertrand ME; Desmet W; Hamon M; Stone GW
    Am J Cardiol; 2014 Dec; 114(11):1638-45. PubMed ID: 25312637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis.
    Bellemain-Appaix A; Kerneis M; O'Connor SA; Silvain J; Cucherat M; Beygui F; Barthélémy O; Collet JP; Jacq L; Bernasconi F; Montalescot G;
    BMJ; 2014 Oct; 349():g6269. PubMed ID: 25954988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of platelet reactivity in patients with acute coronary syndromes.
    Cavallari I; Nusca A; Ricottini E; Di Sciascio G
    Cardiol Rev; 2014; 22(6):313-8. PubMed ID: 25050977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome.
    Olivier CB; Turakhia MP; Mahaffey KW
    Expert Opin Drug Saf; 2018 Mar; 17(3):251-258. PubMed ID: 29363352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.